Differentsial'naya diagnostika osteoartrita i podagry: osnovnye podkhody k terapii
- Authors: Pogozheva E.Y.1, Amirdzhanova V.N1, Karateev A.E1
-
Affiliations:
- V.A.Nasonova Research Institute of Rheumatology
- Issue: Vol 20, No 12 (2018)
- Pages: 122-125
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95150
- DOI: https://doi.org/10.26442/20751753.2018.12.180108
- ID: 95150
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E. Yu Pogozheva
V.A.Nasonova Research Institute of Rheumatology
Email: lifequality@yandex.ru
канд. мед. наук, науч. сотр 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A
V. N Amirdzhanova
V.A.Nasonova Research Institute of Rheumatologyд-р мед. наук, вед. науч. сотр. 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A
A. E Karateev
V.A.Nasonova Research Institute of Rheumatology
Email: aekarat@yandex.ru
д-р мед. наук, рук. лаб. патофизиологии боли и полиморфизма скелетно-мышечных заболеваний 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A
References
- Ревматология. Клинические рекомендации. Под ред. Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2017; с. 240-65.
- Насонов Е.Л. Ревматология. Клинические рекомендации. М.: ГЭОТАР, 2005; с. 264.
- Jordan K.M, Arden N.K, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-55.
- Zhang W, Nuki G, Moskowitz R.W et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476-99.
- Bruyère O, Cooper C, Pelletier J-P et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally. A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars Arthritis Rheum 2014; 44 (3): 253-63.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Остеоартроз. 2016. IDКР256.
- Pelletier J, Yaron M, Haraoui B et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000; 43 (10): 2339-48.
- Pavelka K, Trc T, Karpas K et al. The Efficacy and Safety of Diacerein in the Treatment of Painful Osteoarthritis of the Knee. Arthritis Rheum 2007; 56 (12): 4055-64.
- Louthrenoo W, Nilganuwong S, Aksaranugraha S et al. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage 2007; 15 (6): 605-14.
- Zheng W, Tang F, Li J et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J 2006; 21 (2): 75-80.
- Sharma A, Rathod R, Baliga V.P. An open prospective study on postmarketing evaluation of the efficacy and tolerability of diacerein in osteoarthritis of the knee (DOK). J Indian Med Assoc 2008; 106 (1): 54-6, 58.
- Dougados M, Nguyen M, Berdah L et al. ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in oa of the hip. Arthritis Rheum 2001; 44 (11): 2539-47.
- Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/527347/2014.
- Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29-42.
- Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res 2014; 37 (10): 919-25.
- Whelton A, MacDonald P.A, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med 2013; 125 (1): 106-14.
- Becker M.A, Schumacher H.R, Wortmann R.L et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353 (23): 2450-61.
- Schumacher H.R, Becker M.A, Wortmann R.L et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59 (11): 1540-8.
- Wortmann R.L, Becker M.A, Schumacher H.R et al. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial. ACR/ARHP Annual Scientific Meeting, 2006.
- Becker M.A, Schumacher H.R, Espinoza L.R et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12 (2): R63.
- Schumacher H.R, Becker M.A, Wortmann R.L et al. The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, openlabel extension study [abstract no. OP0130]. Ann Rheum Dis 2006; 65 (Suppl. II): 93.